Compared to the IL-4 (interleukin 4)-treated control, the expression of iNOS (nitric oxide synthase), which causes tumor cell death, significantly increased after the nano-immunomodulator therapy, rising from 19.4% to 96.1% (76.7%) [149]. The gene discussed is IL4; the disease is neoplasm.